The Patent Finder

Viventia Bio Inc.

Also on record
Records under this name other than the patents Viventia Bio Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.

Back to Viventia Bio Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,697,075Cancer specific antibody and cell surface proteins
Term ended
Term ended Dec 21, 2025 · USPTO record
Term endedTerm ended Dec 21, 2025USPTO record
US 9,822,182Anti-EPCAM antibodies and methods of use
Lapsed on the fee record
Ended Nov 21, 2025 · USPTO record
Lapsed on the fee recordEnded Nov 21, 2025USPTO record
US 8,969,540Tumor Specific Antibody
Term ended
Term ended Jun 10, 2025 · Medium confidence
Term endedTerm ended Jun 10, 2025Medium confidence
US 8,389,286Cancer-associated antigen
Lapsed on the fee record
Ended Mar 5, 2025 · USPTO record
Lapsed on the fee recordEnded Mar 5, 2025USPTO record
US 8,318,472Optimized nucleic acid sequences for the expression of VB4-845
Lapsed on the fee record
Ended Nov 27, 2024 · USPTO record
Lapsed on the fee recordEnded Nov 27, 2024USPTO record
US 8,263,744Binding proteins that bind to EpCAM linked to an effector molecule
Lapsed on the fee record
Ended Sep 11, 2024 · USPTO record
Lapsed on the fee recordEnded Sep 11, 2024USPTO record
US 8,426,561Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
Lapsed on the fee record
Ended Apr 23, 2021 · USPTO record
Lapsed on the fee recordEnded Apr 23, 2021USPTO record
US 8,383,117CD44E tumor specific antibody
Formerly held
Lapsed on the fee record
Ended Feb 26, 2021 · USPTO record
Lapsed on the fee recordEnded Feb 26, 2021USPTO record
US 8,273,550Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof
Lapsed on the fee record
Ended Sep 25, 2020 · USPTO record
Lapsed on the fee recordEnded Sep 25, 2020USPTO record
US 6,207,153Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
Term ended
Term ended May 22, 2017 · USPTO record
Term endedTerm ended May 22, 2017USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited